Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

FcRn blockers are approved for other indications: efgartigimod for adults with generalized myasthenia gravis and in ...

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel ...

ABS-201 edge stems on its ability to target the prolactin receptor to promote hair growth while preserving stem cells. It ...

Immatics has innovative TCR therapies, strong cash position, and expanding clinical pipeline targeting solid tumors. Read for ...

Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo Human ex vivo data validate ABS-201’s potential to reverse follicular ...

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the ...

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products ...

The future of dermatology is no longer just skin deep. This year’s American Academy of Dermatology (AAD) annual meeting was held March 7-11, 2025, in Orlando, FL, and it showcased the specialty’s ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. today announced positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial ...

AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union (EU) for subcutaneous self-administration as a pre-filled pen for adult patients with systemic lupus erythematosus (SLE) on ...